Mission and Focus

The company's central mission is to turn the promise of genetic medicine into a reality for patients suffering from rare neurological diseases where treatment options are extremely limited or nonexistent. Many of these conditions are caused by mutations in a single gene, making them potential candidates for gene therapy interventions designed to correct, replace, or regulate the affected genetic material.

Neurogene concentrates on diseases that primarily affect the central nervous system and are frequently characterized by progressive neurological decline, developmental regression, and reduced life expectancy. By pursuing genetic medicine, the company aims to alter the underlying course of these disorders rather than merely treating their symptoms.

Technology Platform

A key differentiator for Neurogene is its proprietary technology known as EXACT (Expression Attenuation via Construct Tuning). This platform was developed to address a fundamental challenge in gene therapy: delivering the appropriate level of a therapeutic gene product. In many neurological disorders, both too little and too much of a given protein can be harmful. Traditional gene therapy approaches can risk overexpression, which may lead to toxicity.

The EXACT technology is designed to enable more precise, regulated expression of a therapeutic transgene within a physiologically relevant range. This allows the delivery of genes that require tight control of protein levels, expanding the range of diseases that may be safely and effectively addressed with gene therapy. The platform represents an important advance for conditions where dosage sensitivity has historically posed a barrier to conventional gene replacement strategies.

Product Candidates and Pipeline

Neurogene's development efforts are organized around a pipeline of gene therapy candidates targeting specific rare neurological conditions.

NGN-401 for Rett Syndrome

The company's lead clinical program is NGN-401, a gene therapy candidate for the treatment of Rett syndrome. Rett syndrome is a severe, progressive neurodevelopmental disorder caused by mutations in the MECP2 gene. It predominantly affects females and leads to loss of acquired skills, impaired motor function, seizures, breathing abnormalities, and other debilitating symptoms.

Rett syndrome is a particularly challenging target for gene therapy because the MECP2 protein must be expressed within a narrow therapeutic window. Insufficient MECP2 fails to correct the disease, while excessive MECP2 causes its own severe neurological syndrome. NGN-401 utilizes the EXACT technology to deliver a full-length human MECP2 gene while regulating its expression, aiming to provide therapeutic benefit while avoiding the toxicity associated with overexpression. NGN-401 is being evaluated in clinical trials designed to assess its safety and efficacy in patients with Rett syndrome.

Additional Pipeline Programs

Beyond its lead program, Neurogene has pursued preclinical and research-stage candidates targeting other rare neurological diseases. These have included programs directed at conditions such as CLN5 Batten disease, a form of neuronal ceroid lipofuscinosis, which is a group of inherited neurodegenerative disorders affecting children. The company's broader research efforts leverage its expertise in adeno-associated virus (AAV) based gene delivery and its regulated expression technology to explore additional indications where genetic medicine may offer meaningful benefit.

Approach to Gene Therapy

Neurogene relies on adeno-associated virus vectors as the delivery vehicle for its gene therapies. AAV vectors are widely used in the gene therapy field because of their favorable safety profile and their ability to deliver genetic material to non-dividing cells such as neurons. The company's therapies are typically designed for delivery to the central nervous system in order to reach the affected tissues.

The combination of AAV delivery with the EXACT expression-regulation platform is intended to allow Neurogene to pursue diseases that have been difficult to treat with earlier generations of gene therapy technology, particularly those requiring careful control over therapeutic protein levels.

Manufacturing and Development Capabilities

Neurogene has invested in building internal capabilities to support the development and manufacturing of its gene therapy products. Establishing robust, scalable, and high-quality manufacturing processes is a critical component of advancing gene therapies from research through clinical trials and toward potential commercialization. The company's focus on internal expertise is intended to support consistency, quality control, and the specialized requirements of producing AAV-based genetic medicines.

Patient and Community Commitment

As a company focused on rare pediatric and neurological diseases, Neurogene emphasizes partnership with patient communities, families, caregivers, advocacy organizations, and clinicians. These relationships are important for understanding the natural history of the diseases it targets, informing clinical trial design, and ensuring that development efforts remain aligned with the needs and priorities of affected families. Rare disease drug development often depends heavily on collaboration with patient advocacy groups given the small and geographically dispersed patient populations involved.

Summary

Neurogene Inc. is a clinical-stage biotechnology company committed to developing genetic medicines for rare and devastating neurological diseases. Through its proprietary EXACT expression-regulation technology and AAV-based gene delivery approach, the company seeks to address conditions where precise control of gene expression is essential. Its lead program, NGN-401 for Rett syndrome, exemplifies its strategy of tackling diseases with high unmet need and challenging biological requirements. With a mission centered on transforming the lives of patients and families, Neurogene aims to expand the boundaries of what gene therapy can achieve for serious neurological disorders.